{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:58:56Z","timestamp":1768885136968,"version":"3.49.0"},"reference-count":42,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>The most common and lethal consequence of chronic kidney disease (CKD) is atherosclerotic cardiovascular disease. The persistent inflammation present in CKD increases hepcidin levels. Iron accumulates in the arterial wall in atherosclerosis. Hepcidin-25 was thought to accelerate the development of atherosclerotic plaques by blocking iron release from macrophages. Therefore, we sought to determine the relationship between hepcidin-25 and asymptomatic atherosclerosis in non-dialysis CKD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Investigate the relationship between hepcidin-25 and subclinical atherosclerosis in non-dialysis CKD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Cross-sectional<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTINGS:<\/jats:title>\n            <jats:p>Outpatient clinic for urology and nephrology at a university hospital<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SUBJECTS AND METHODS:<\/jats:title>\n            <jats:p>Participants above the age of 18 years included a group of healthy controls and a group of CKD patients who were not routinely maintained on hemodialysis. The latter group was further divided according to eGFR into CKD-3, CKD-4 and CKD-5 subgroups. We excluded patients with comorbidities, patients with chronic liver disease, and other conditions or habits. CBC, kidney function tests, and serum levels of hepcidin-25 (SH-25), TNF-\u03b1, IL-6, high-sensitivity C-reactive protein (hs-CRP), TC, TG, LDL-C and HDL-C were assessed. To measure carotid intima media thickness (CIMT) and determine presence of plaques, carotid ultrasonography was performed. The near or far walls of common carotid artery, bulb, and internal carotid artery were used to measure CIMT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>SH-25 association and indicators of subclinical atherosclerosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SAMPLE SIZE:<\/jats:title>\n            <jats:p>128 participants, the control group (n=25) and the non-hemodialysis CKD patients (n=103)<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              The CKD patients had significantly higher serum levels of markers of inflammation including IL-6, TNF-\u03b1, and hs-CRP (\n              <jats:italic>P<\/jats:italic>\n              &lt;.001 for each) compared to the controls. There was a significantly higher level of TC, TG and LDL-C (\n              <jats:italic>P<\/jats:italic>\n              &lt;.001 for each) and a lower level of HDL-C (\n              <jats:italic>P<\/jats:italic>\n              &lt;.001) in the CDK patients compared to controls. SH-25 was considerably higher in all CKD subgroups, especially with progression of CKD. CIMT was increased in CKD patients especially CKD-4 and CKD-5 subgroups when compared to healthy participants (\n              <jats:italic>P<\/jats:italic>\n              &lt;.001 for each). In the patient group, CIMT showed a positive correlation with SH-25, (r=.65 and\n              <jats:italic>P<\/jats:italic>\n              &lt;.001), IL-6 (r=.65,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001), TNF-\u03b1 (r=.71,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001), and hs-CRP (r=.52,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001). The ROC curve study showed that SH-25 (AUC=.86,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001), IL-6 (AUC=.83,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001), hs-CRP (AUC=.72,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001), TNF-\u03b1 (AUC=.82,\n              <jats:italic>P<\/jats:italic>\n              &lt;.001) were strong predictors of subclinical atherosclerosis in the CKD patients.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>SH-25 and CIMT had a positive relationship in CKD patients. The ROC curve showed that SH-25 is a reliable predictor of carotid atherosclerosis. Therefore, we suggest that SH-25 is a vital biomarker of asymptomatic atherosclerosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Single-center<\/jats:p>\n          <\/jats:sec>","DOI":"10.5144\/0256-4947.2023.298","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T08:58:48Z","timestamp":1696841928000},"page":"298-308","source":"Crossref","is-referenced-by-count":3,"title":["The relationship between asymptomatic atherosclerosis and hepcidin-25 in chronic kidney disease patients"],"prefix":"10.5144","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7627-0617","authenticated-orcid":false,"given":"Osama Nady","family":"Mohamed","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mohamed","family":"Mady","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Mamdouh","family":"Sedik","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S.","family":"Issa","sequence":"additional","affiliation":[{"name":"From the Department of Radiology, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omima M.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia Ismail","family":"Abdelhameed","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"issue":"1","key":"e_1_3_2_2_2","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin A","year":"2013","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3(1):1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/ATVBAHA.119.312705","article-title":"Atherosclerosis in chronic kidney disease: more, less, or just different?","volume":"39","author":"Valdivielso JM","year":"2019","unstructured":"Valdivielso JM, Rodr\u00edguez-Puyol D, Pascual J, Barrios C, Berm\u00fadez-L\u00f3pez M, S\u00e1nchez-Ni\u00f1o MD, et al. Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol. 2019;39(10):1938\u20131966.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"104664","DOI":"10.1016\/j.phrs.2020.104664","article-title":"The role of hepcidin and iron homeostasis in atherosclerosis","volume":"153","author":"Wunderer F","year":"2020","unstructured":"Wunderer F, Traeger L, Sigurslid HH, Meybohm P, Bloch DB, Malhotra R. The role of hepcidin and iron homeostasis in atherosclerosis. Pharmacol Res. 2020;153:104664.","journal-title":"Pharmacol Res"},{"issue":"12","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1093\/ndt\/gfs488","article-title":"Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients","volume":"28","author":"van der Weerd NC","year":"2013","unstructured":"van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrology, Dialysis, Transplantation. 2013; 28(12):3062\u20133071.","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ebiom.2019.08.014","article-title":"New insights into the role of iron in inflammation and atherosclerosis","volume":"47","author":"Cornelissen A","year":"2019","unstructured":"Cornelissen A, Guo L, Sakamoto A, Virmani R, Finn AV. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine. 2019;47: 598\u2013606.","journal-title":"EBioMedicine"},{"issue":"4","key":"e_1_3_2_7_2","first-page":"209","article-title":"Serum hepcidin levels and cardiovascular outcomes in patients on maintenance hemodialysis: a study from South India","volume":"22","author":"Anupama KV","year":"2022","unstructured":"Anupama KV and Yadla M, Serum hepcidin levels and cardiovascular outcomes in patients on maintenance hemodialysis: a study from South India. JESNT. 2022; 22(4):209.","journal-title":"JESNT"},{"key":"e_1_3_2_8_2","first-page":"117","article-title":"Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients","volume":"19","author":"Yayar \u00d6","year":"2018","unstructured":"Yayar \u00d6, Eser B and K\u0131l\u0131\u00e7 H, Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients. Anatol J Cardiol 2018; 19:117\u2013122.","journal-title":"Anatol J Cardiol"},{"issue":"2","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/hdi.12355","article-title":"Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients?","volume":"20","author":"Kali A","year":"2016","unstructured":"Kali A, Yayar O, Erdogan B, Eser B, Buyukbakkal M, Ercan Z, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int. 2016; 20(2):191\u2013197.","journal-title":"Hemodial Int"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"684548","DOI":"10.3389\/fmed.2021.684548","article-title":"Serum hepcidin-25 and risk of mortality in patients on peritoneal dialysis","volume":"8","author":"Zhong Z","year":"2021","unstructured":"Zhong Z, Luo D, Luo N, Li B, Fu D, Fan L, et al. Serum hepcidin-25 and risk of mortality in patients on peritoneal dialysis. Front Med. 2021; 8: 684548.","journal-title":"Front Med"},{"issue":"4","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/hr.2012.192","article-title":"A cutoff point for arterial stiffness using the cardio-ankle vascular index based on carotid riosclerosis","volume":"36","author":"Hu H","year":"2013","unstructured":"Hu H, Cui H, Han W, Ye L, Qiu W, Yang H, et al. A cutoff point for arterial stiffness using the cardio-ankle vascular index based on carotid riosclerosis. Hypertens Res. 2013; 36(4):334\u2013341.","journal-title":"Hypertens Res"},{"issue":"1","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000368940","article-title":"Update on inflammation in chronic kidney disease","volume":"39","author":"Akchurin M","year":"2015","unstructured":"Akchurin M, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015; 39(1-3):84\u201392.","journal-title":"Blood Purif"},{"issue":"12","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2215\/CJN.03500412","article-title":"Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC","volume":"7","author":"Gupta J","year":"2012","unstructured":"Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 7(12):1938\u20131946.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"e_1_3_2_14_2","first-page":"1","article-title":"Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients","volume":"13","author":"Kim JK","year":"2013","unstructured":"Kim JK, Song YR, Kim MG, Kim HJ, Kim SG. Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. BMC Cardiovasc Disord. 2013; 13(1):1\u201310.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0003319713483000","article-title":"Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4","volume":"65","author":"Ghanavatian S","year":"2014","unstructured":"Ghanavatian S, Diep LM, B\u00e1r\u00e1ny P, Heimb\u00fcrger O, Seeberger A, Stenvinkel P, et al. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. Angiology. 2014; 65(5):443\u2013449.","journal-title":"Angiology"},{"issue":"1","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5414\/CNP92S114","article-title":"Interleukin-6 gene polymorhisms and interleukin-6 levels are associated with atherosclerosis in CKD patients","volume":"93","author":"Hassan MO","year":"2010","unstructured":"Hassan MO, Duarte R, Dickens C, Dix-Peek T, Naidoo S, Vachiat A, et al. Interleukin-6 gene polymorhisms and interleukin-6 levels are associated with atherosclerosis in CKD patients. Clin Nephrol. 2010; 93(1):82\u201386.","journal-title":"Clin Nephrol"},{"issue":"3","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur RL","year":"2019","unstructured":"Amdur RL, Feldman HR, Dominic EA, Anderson AH, Beddhu S, Rahman M, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis. 2019;73(3):344\u2013353.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.22159\/ijpps.2020v12i8.38221","article-title":"Comparative study of lipid profile in patients of non-diabetic chronic kidney disease in relation to its severity","volume":"12","author":"Behera BP","year":"2020","unstructured":"Behera BP. Comparative study of lipid profile in patients of non-diabetic chronic kidney disease in relation to its severity. Int J Pharm Pharm Sci. 2020; 12(8):142\u2013148.","journal-title":"Int J Pharm Pharm Sci"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/IJNRD.S101808","article-title":"Dyslipidemia in patients with chronic kidney disease: etiology and management","volume":"10","author":"Mikolasevic I","year":"2017","unstructured":"Mikolasevic I, \u017dutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11154-016-9402-z","article-title":"Dyslipidemia in patients with chronic kidney disease","volume":"18","author":"Hager MR","year":"2017","unstructured":"Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18(1):29\u201340.","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"E376","DOI":"10.3390\/toxins8120376","article-title":"Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins","volume":"8","author":"Florens N","year":"2016","unstructured":"Florens N, Calzada C, Lyasko E, Juillard L, Soulage C. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel). 2016;8(12):E376.","journal-title":"Toxins (Basel)"},{"issue":"11","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2215\/CJN.02090212","article-title":"CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis","volume":"7","author":"Lamprea-Montealegre JA","year":"2012","unstructured":"Lamprea-Montealegre JA, Astor BC, Mc-Clelland RL, de Boer IH, Burke GL., Sibley CT, et al. CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2012;7(11):1777\u20131785.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"e_1_3_2_23_2","first-page":"251","article-title":"Studying the relationship between the risk factors of cardiovascular diseases and carotid intima-media thickness (CIMT) in renal patients undergoing hemodialysis admitted to Razi Hospital and Caspian Dialysis Center in Rasht","volume":"13","author":"Arzpeyma SF","year":"2018","unstructured":"Arzpeyma SF, Saheli YH, Sattarzadeh AB, Leyli EK. Studying the relationship between the risk factors of cardiovascular diseases and carotid intima-media thickness (CIMT) in renal patients undergoing hemodialysis admitted to Razi Hospital and Caspian Dialysis Center in Rasht. Revista latinoamericana de hipertensi\u00f3n. 2018;13(3):251.","journal-title":"Revista latinoamericana de hipertensi\u00f3n"},{"issue":"112","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.01240215","article-title":"Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD","author":"Gracia M","year":"2016","unstructured":"Gracia, M, \u00c0ngels B Montserrat MA, David A, Mar\u00eda A, Elvira F, et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. 2016;(112):287\u2013296.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.07320619","article-title":"Apolipoprotein B, triglyceride-rich lipo-proteins, and risk of cardiovascular events in persons with CKD","volume":"15","author":"Lamprea-Montealegre JA","year":"2020","unstructured":"Lamprea-Montealegre JA, Natalie S, William GH, Richard H, Jonathan E, Colin B, et al. Apolipoprotein B, triglyceride-rich lipo-proteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol. 2020;15(1):47\u201360.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/07853890.2010.532153","article-title":"Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease","volume":"44","author":"Holzmann MJ","year":"2012","unstructured":"Holzmann MJ, Jungner I, Walldius G, Ivert T, Nordqvist T, Ostergren J, et al. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Ann Med. 2012;44(3):262\u2013270.","journal-title":"Ann Med"},{"issue":"4","key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/ejim.ejim_31_18","article-title":"Study of hepcidin level in patients with chronic kidney disease and its correlation with markers of iron status in Zagazig University Hospital","volume":"30","author":"Kamal NM","year":"2018","unstructured":"Kamal NM, Diab M, Khalil RA. Study of hepcidin level in patients with chronic kidney disease and its correlation with markers of iron status in Zagazig University Hospital. Egypt J Intern Med. 2018;30(4): 284\u2013288.","journal-title":"Egypt J Intern Med"},{"issue":"11","key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ajh.20657","article-title":"Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis","volume":"8","author":"Malyszko J","year":"2006","unstructured":"Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. (2006). Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol. 2006;8(11):832\u2013837.","journal-title":"Am J Hematol"},{"issue":"3","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ndt\/gfr431","article-title":"Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study","volume":"27","author":"Uehata T","year":"2012","unstructured":"Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrology, Dialysis, Transplantation. 2012;27(3):1076\u20131083.","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.9734\/jpri\/2020\/v32i1230558","article-title":"Serum Hepcidin as an Inflammatory Marker in Chronic Kidney Disease","author":"Roy JE","year":"2020","unstructured":"Roy JE, Shanthi B, Selvi VK. Serum Hepcidin as an Inflammatory Marker in Chronic Kidney Disease. J Pharm Res Int. 2020;40\u201345.","journal-title":"J Pharm Res Int"},{"issue":"9","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1177\/0300060518781619","article-title":"Chronic kidney disease is associated with carotid atherosclerosis and symptomatic ischaemic stroke","volume":"46","author":"Kajitani N","year":"2018","unstructured":"Kajitani N, Uchida HA, Suminoe I, Kakio Y, Kitagawa M, Sato H, et al. Chronic kidney disease is associated with carotid atherosclerosis and symptomatic ischaemic stroke. J Int Med Res. 2018;46(9):3873\u20133883.","journal-title":"J Int Med Res"},{"issue":"2","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/ATVBAHA.111.240101","article-title":"Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis","volume":"32","author":"Saeed O","year":"2012","unstructured":"Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, Davis T, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32(2):299\u2013307.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/ATVBAHA.112.246108","article-title":"Hepcidin destabilizes athero-sclerotic plaque via overactivating macrophages after erythrophagocytosis","volume":"32","author":"Li JJ","year":"2012","unstructured":"Li JJ, Meng X, Si HP, Zhang C, Lv HX, Zhao YX, et al. Hepcidin destabilizes athero-sclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012; 32(5):1158\u20131166.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/ndt\/gfq760","article-title":"Hepcidin as well as TNF-\u03b1 are significant predictors of arterial stiffness in patients on maintenance hemodialysis","volume":"26","author":"Kuragano T","year":"2011","unstructured":"Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, et al. Hepcidin as well as TNF-\u03b1 are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrology, Dialysis, Transplantation. 2011; 26(8):2663\u20132667.","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"3","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/ATVBAHA.110.214858","article-title":"Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations","volume":"31","author":"Valenti L","year":"2011","unstructured":"Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol. 2011; 31(3):683\u2013690.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/ATVBAHA.113.302381","article-title":"Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population","volume":"34","author":"Galesloot TE","year":"2014","unstructured":"Galesloot TE, Holewijn S, Kiemeney L.A, de Graaf J, Vermeulen SH, Swinkels DW. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol. 2014; 34(2):446\u2013456.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.atherosclerosis.2015.06.025","article-title":"Hepcidinferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques","volume":"241","author":"Habib A","year":"2015","unstructured":"Habib A, Polavarapu R, Karmali V, Guo L, Van Dam R, Cheng Q, et al. Hepcidinferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques. Atherosclerosis. 2015; 241(2): 692\u2013700.","journal-title":"Atherosclerosis"},{"issue":"6","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2215\/CJN.08161109","article-title":"Reduction of serum hepcidin by hemodialysis in pediatric and adult patients","volume":"5","author":"Zaritsky J","year":"2010","unstructured":"Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010; 5(6):1010.","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s11255-014-0753-7","article-title":"Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients","volume":"46","author":"Ulu SM","year":"2014","unstructured":"Ulu SM, Yuksel S, Altunta\u015f A, Kacar E, Ahsen A, Altug A, et al. Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol. 2014; 46: 2409\u20132414.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1515\/cclm-2015-0068","article-title":"Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population","volume":"54","author":"Pechlaner R","year":"2016","unstructured":"Pechlaner R, Kiechl S, Mayr M, Santer P, Weger S, Haschka D, et al. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population. Clin Chem Lab Med. 2016; 54(1):151\u2013161.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"e0134635","DOI":"10.1371\/journal.pone.0134635","article-title":"Iron stores, hepcidin, and aortic stiffness in individuals with hypertension","volume":"10","author":"Valenti L","year":"2015","unstructured":"Valenti L, Maloberti A, Signorini S, Milano M, Cesana F, Cappellini F, et al. Iron stores, hepcidin, and aortic stiffness in individuals with hypertension. PloS one. 2015;10(8): e0134635.","journal-title":"PloS one"},{"issue":"3","key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2011-02-337212","article-title":"Low hepcidin accounts for the proinflammatory status associated with iron deficiency","volume":"118","author":"Pagani A","year":"2011","unstructured":"Pagani A, Nai A, Corna G, Bosurgi L, Rovere-Querini P, Camaschella C et al. Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood. 2011;118(3): 736\u2013746.","journal-title":"Blood"},{"issue":"6","key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5527\/wjn.v1.i6.166","article-title":"Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease","volume":"1","author":"Canavesi E","year":"2012","unstructured":"Canavesi E, Alfieri C, Pelusi S and Valenti L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol. 2012; 1(6):166.","journal-title":"World J Nephrol"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:04:09Z","timestamp":1696849449000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2023.298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.5144\/0256-4947.2023.298"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2023.298","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}